Loading clinical trials...
Loading clinical trials...
Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency
Conditions
Interventions
Pembrolizumab 200 mg Q3W
Locations
1
United States
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, United States
Start Date
November 3, 2017
Primary Completion Date
October 20, 2020
Completion Date
March 19, 2022
Last Updated
October 19, 2023
NCT06625775
NCT05223608
NCT06051695
NCT06265727
NCT04665206
NCT05036226
Lead Sponsor
Baptist Health South Florida
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions